ArticleFrontiers in reproductive health2026
Prophylactic antibiotic regimen and risk of surgical site infection in patients undergoing hysterectomy for benign disease: a retrospective cohort study.
Article in Frontiers in reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the association between prophylactic antibiotic regimen (cefazolin alone vs. cefazolin plus metronidazole) and the occurrence of surgical site infections (SSIs), as well as infection severity and management, in patients undergoing hysterectomy for benign disease. Methods: A retrospective cohort study was conducted at a tertiary care center, including women undergoing hysterectomy for benign indications. Patients receiving cefazolin alone were compared with those receiving cefazolin plus metronidazole. The primary outcome was overall SSIs. Secondary outcomes included infection severity (superficial, deep, organ/space) and type of management (medical vs. surgical). Crude associations were estimated using contingency tables, and adjusted odds ratios were obtained through multivariable logistic regression including clinically relevant covariates. Results: A total of 1,069 patients were included, of whom 512 received cefazolin alone and 557 received cefazolin plus metronidazole. In the adjusted analysis, the combined regimen was not associated with a reduced risk of SSIs (aORs: 1.02; 95% CI: 0.60-1.76; Conclusion: The addition of metronidazole to cefazolin was not associated with a reduction in overall SSIs incidence after hysterectomy for benign disease. However, it was associated with lower infection severity and reduced need for surgical reintervention among patients who developed SSIs, suggesting a potential benefit in reducing postoperative morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.